Lung Cancer Management

期刊简介：The strong link between smoking rates and lung cancer incidence has resulted in varying rates of disease within different populations whether on a geographic, socioeconomic or gender basis. What is clear is that, in spite of declining disease rates among some groups in certain developed countries, the disease remains a highly significant global burden. For example, the National Institute of Health estimates that cancer care cost the United States an overall $124.6 billion in 2010, $12.1 billion of which was due to lung cancer. Surgery, radiotherapy and chemotherapy – alone or in combination – all have a role to play in the treatment of lung cancer. Lung Cancer Management addresses key issues and current understanding in the diagnosis, staging and treatment of disease by exploring the best patient-centered clinical research and presenting this information both directly, as clinical findings, and in practice-oriented formats of direct relevance in the clinic. Lung Cancer Management provides oncologists and other health professionals with the latest findings and opinions on reducing the burden of this widespread disease. Recent research findings and advances in clinical practice in the field are reported and analyzed by international experts, and the importance of the most recent advances in molecular biology are explained. The journal presents this information in clear, accessible formats. All articles are subject to independent review by a minimum of three independent experts. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal’s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3. Coverage includes: Biological therapies Biomarkers Clinical trials Comparative effectiveness Diagnosis and imaging Molecular biology of disease Molecular diagnostics Pharmacoeconomics Radiotherapy Risk and prevention Surgical approaches Systemic therapies

【译文】吸烟率与肺癌发病率之间的密切联系导致不同人群的患病率不同，无论是在地理、社会经济还是性别方面。显而易见的是，尽管某些发达国家某些群体的发病率有所下降，但该疾病仍然是一个非常严重的全球负担。例如，美国国立卫生研究院估计，2010 年美国癌症治疗费用总计为 1,246 亿美元，其中 121 亿美元是肺癌造成的。手术、放疗和化疗——单独或联合——都在肺癌的治疗中发挥着作用。肺癌管理通过探索最佳的以患者为中心的临床研究，并以临床发现的形式直接呈现这些信息，并以与临床直接相关的以实践为导向的形式，解决疾病诊断、分期和治疗方面的关键问题和当前的理解。肺癌管理为肿瘤学家和其他卫生专业人员提供有关减轻这种广泛疾病负担的最新发现和意见。国际专家报告和分析了该领域临床实践的最新研究成果和进展，并解释了分子生物学最新进展的重要性。该杂志以清晰易懂的格式呈现这些信息。所有文章均须接受至少三名独立专家的独立审查。欢迎主动提出的文章提案，作者必须完全遵守期刊的披露和利益冲突政策以及主要出版指南，包括 ICMJE 和 GPP3。覆盖范围包括： 生物疗法 生物标志物 临床试验 有效性比较 诊断和成像 疾病的分子生物学 分子诊断 药物经济学 放射治疗 风险和预防 手术方法 全身治疗